Of these, only the Imatinib and pan-Bcl2 family gene inhibitor combination described by Meng et al. and Goff et al. restored the normal phenotype in the CP CML state without changing the WT population from the baseline state31, 32. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.